Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Operations: 2017-2025

Historic Cash from Operations for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to -$110.7 million.

  • Crinetics Pharmaceuticals' Cash from Operations fell 76.24% to -$110.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$347.7 million, marking a year-over-year decrease of 72.25%. This contributed to the annual value of -$226.0 million for FY2024, which is 35.88% down from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Cash from Operations is -$110.7 million, which was down 28.97% from -$85.9 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Cash from Operations' 5-year high stood at -$13.5 million during Q1 2022, with a 5-year trough of -$110.7 million in Q3 2025.
  • Its 3-year average for Cash from Operations is -$61.6 million, with a median of -$52.9 million in 2024.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Cash from Operations soared by 32.51% in 2022 and then slumped by 200.66% in 2023.
  • Crinetics Pharmaceuticals' Cash from Operations (Quarterly) stood at -$22.9 million in 2021, then tumbled by 53.75% to -$35.2 million in 2022, then decreased by 9.40% to -$38.5 million in 2023, then slumped by 62.66% to -$62.6 million in 2024, then tumbled by 76.24% to -$110.7 million in 2025.
  • Its last three reported values are -$110.7 million in Q3 2025, -$85.9 million for Q2 2025, and -$88.5 million during Q1 2025.